Chargement en cours...
Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice
Prasugrel and ticagrelor are two novel promising antiplatelet agents inhibiting the platelet activation via the adenosine diphosphate pathway. Both achieve a faster, more intense, and more consistent platelet inhibition than clopidogrel. Both novel antiplatelet agents have demonstrated superiority o...
Enregistré dans:
| Publié dans: | Interv Cardiol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Radcliffe Cardiology
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5844017/ https://ncbi.nlm.nih.gov/pubmed/29588796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/icr.2014.9.3.164 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|